PURPOSE: According to the World Health Organization (WHO) classification of pulmonary large cell neuroendocrine carcinoma (LCNEC), one of the neuroendocrine tumors of the lung, is considered as a variant of non-small cell lung carcinoma. The objective of this study was to investigate the treatment strategy for LCNEC. METHODS: We retrospectively reviewed the clinical information of 12 patients with LCNEC. RESULTS: Three patients with stage I disease underwent curative resection but all relapsed within 20 months. One with stage IIA disease underwent non-curative resection received adjuvant chemoradiotherapy (cisplatin plus etoposide) and is well with no evidence of recurrence. Two with stage IIIB disease received concurrent chemoradiotherapy. Both achieved partial response (PR) but relapsed within 2 months. One elderly patient with stage IIIA disease received vinorelbine alone and did not respond. Of five patients with stage IV disease, three received platinum-based chemotherapy but no patient achieved PR. Of five patients with gefitinib as salvage therapy, one achieved PR. CONCLUSIONS: The prognosis of LCNEC is poor. To improve the outcome, we must evaluate the effectiveness of adjuvant or neoadjuvant therapy in patients with resectable disease. In addition, the evaluation of systemic and multimodality treatment strategies similar as in small cell lung cancer is worthy of consideration.
PURPOSE: According to the World Health Organization (WHO) classification of pulmonary large cell neuroendocrine carcinoma (LCNEC), one of the neuroendocrine tumors of the lung, is considered as a variant of non-small cell lung carcinoma. The objective of this study was to investigate the treatment strategy for LCNEC. METHODS: We retrospectively reviewed the clinical information of 12 patients with LCNEC. RESULTS: Three patients with stage I disease underwent curative resection but all relapsed within 20 months. One with stage IIA disease underwent non-curative resection received adjuvant chemoradiotherapy (cisplatin plus etoposide) and is well with no evidence of recurrence. Two with stage IIIB disease received concurrent chemoradiotherapy. Both achieved partial response (PR) but relapsed within 2 months. One elderly patient with stage IIIA disease received vinorelbine alone and did not respond. Of five patients with stage IV disease, three received platinum-based chemotherapy but no patient achieved PR. Of five patients with gefitinib as salvage therapy, one achieved PR. CONCLUSIONS: The prognosis of LCNEC is poor. To improve the outcome, we must evaluate the effectiveness of adjuvant or neoadjuvant therapy in patients with resectable disease. In addition, the evaluation of systemic and multimodality treatment strategies similar as in small cell lung cancer is worthy of consideration.
Authors: K Goto; T Kodama; F Hojo; K Kubota; R Kakinuma; T Matsumoto; H Ohmatsu; I Sekine; K Nagai; Y Nishiwaki Journal: Cancer Date: 1998-03-15 Impact factor: 6.860
Authors: René Hage; Kees Seldenrijk; Peter de Bruin; Henry van Swieten; Jules van den Bosch Journal: Eur J Cardiothorac Surg Date: 2003-04 Impact factor: 4.191
Authors: Christophe Doddoli; Fabrice Barlesi; Bruno Chetaille; Louise Garbe; Pascal Thomas; Roger Giudicelli; Pierre Fuentes Journal: Ann Thorac Surg Date: 2004-04 Impact factor: 4.330
Authors: M Takada; Y Kusunoki; N Masuda; K Matui; T Yana; S Ushijima; K Iida; K Tamura; T Komiya; I Kawase; N Kikui; H Morino; M Fukuoka Journal: Br J Cancer Date: 1996-05 Impact factor: 7.640
Authors: Maria Cattoni; Eric Vallières; Lisa M Brown; Amir A Sarkeshik; Stefano Margaritora; Alessandra Siciliani; Pier Luigi Filosso; Francesco Guerrera; Andrea Imperatori; Nicola Rotolo; Farhood Farjah; Grace Wandell; Kimberly Costas; Catherine Mann; Michal Hubka; Stephen Kaplan; Alexander S Farivar; Ralph W Aye; Brian E Louie Journal: World J Surg Date: 2019-07 Impact factor: 3.352
Authors: Pier Luigi Filosso; Piero Ferolla; Francesco Guerrera; Enrico Ruffini; William D Travis; Giulio Rossi; Paolo Olivo Lausi; Alberto Oliaro Journal: J Thorac Dis Date: 2015-04 Impact factor: 2.895
Authors: Juliane Rieber; Julian Schmitt; Arne Warth; Thomas Muley; Jutta Kappes; Florian Eichhorn; Hans Hoffmann; Claus Peter Heussel; Thomas Welzel; Jürgen Debus; Michael Thomas; Martin Steins; Stefan Rieken Journal: Eur J Med Res Date: 2015-08-14 Impact factor: 2.175
Authors: Arsela Prelaj; Sara Elena Rebuzzi; Gabriella Del Bene; Julio Rodrigo Giròn Berrìos; Alessandra Emiliani; Lucilla De Filippis; Alessandra Anna Prete; Silvia Pecorari; Gaia Manna; Carla Ferrara; Daniele Rossini; Flavia Longo Journal: ERJ Open Res Date: 2017-03-29